India · Delayed Price · Currency is INR Nephrocare Health Services Earnings Call Transcripts
Fiscal Year 2027
-
Q1 FY 2027 saw 23.7% revenue growth and 31% adjusted EBITDA growth, driven by higher treatment volumes and international expansion, with margins and ROCE improving year-on-year. The network reached 550 clinics, and international operations now contribute 45% of revenue.
Fiscal Year 2026
-
Revenue grew 32% YoY to INR 998.8 crore, with adjusted EBITDA up 37% and PAT up 75%, driven by international expansion and operational leverage. RPT rose 13.3% to INR 2,598, and ROCE improved to 22.8%. Guidance remains at 15%-20% CAGR over 3-4 years.
-
Revenue grew 32% YoY in Q3 and 37% for nine months FY 2026, with international business now 41% of revenue. Adjusted EBITDA margin rose to 24.3%, and ROCE is projected to reach 24.7%. Guidance is for 15%-20% revenue CAGR over 3-4 years.